Tag: Prescription Drugs

Displaying 121 - 140 of 153 results.

To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release...
Preserving competition in U.S. markets for three generic pharmaceuticals, the Federal Trade Commission today approved Novartis AG’s (Novartis) $1.72 billion acquisition of Eon Labs, Inc. (Eon), provided Novartis divests three overlapping drugs to Amide Pharmaceutical, Inc. (Amide).
The Federal Trade Commission today filed a petition with the Court of Appeals for the Eleventh Circuit, in Atlanta, Georgia, requesting that the Court vacate its March 8, 2005 decision in the matter of FTC v. Schering-Plough Corporation, No. 04-10688, and re-hear the case en banc.
Commission response to Food and Drug Administration citizen petition: The Commission has authorized the submission of a response to the U.S. Food and Drug Administration (FDA) regarding a citizen petition filed with the FDA by IVAX Pharmaceuticals, Inc. (IVAX) on January 5, 2005. The petition...
Commission authorization of the staff to file amicus brief: The Commission has authorized the staff to file a brief as amicus curiae in Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc., Case No. 04-1186 (Fed. Cir.) in support of Teva’s petition for rehearing or rehearing en banc. The case, which was...
Commission approval of final consent order: Following a public comment period, the Commission has approved a final consent order in the matter concerning Genzyme Corporation and ILEX Oncology, Inc. The Commission vote approving the final consent order was 4-0-1, with Commissioner Pamela Jones...
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an...
The Federal Trade Commission today announced that it will conditionally allow Genzyme Corporation’s (Genzyme) proposed $1 billion acquisition of ILEX Oncology, Inc. (Ilex), provided the companies divest overlapping assets in the U.S. market for solid organ transplant (SOT) acute therapy drugs....
Generic drug manufacturers Alpharma, Inc. and Perrigo Company will give up $6.25 million in illegal profits to settle Federal Trade Commission charges that their agreement to limit competition for over-the-counter (OTC) store-brand children’s liquid ibuprofen drove up prices and violated federal...
The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order...
The consent order settled antitrust concerns that Sanofi's proposed $64 billion acquisition of Aventis would create significant overlaps in several markets for pharmaceutical products while creating the world's third largest pharmaceutical company. Under terms of the consent order,...
By a 3-1-1 vote, the Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme). At the time of its acquisition, Novazyme was engaged primarily in conducting early pre-clinical studies relating to...
A final consent order permits Pfizer Inc.'s acquisition of Phamacia Corporation while requiring the divestiture of various products including extended release drugs used in the treatment of an overactive bladder; hormone replacement therapies; erectile dysfunction; canine arthritis;...
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful...
Baxter settled Commission concerns stemming from its $316 million proposed acquisition of Wyeth Corporation's generic injectable drug business and agreed to divest several pharmaceutical products. The Commission charged that the acquisition would reduce competition in the manufacture...
Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and...
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed...
The Commission negotiated an agreement with The Hearst Corporation (Hearst) to settle a permanent injunction action filed by the FTC alleging that Hearst failed to provide documents required by premerger notification law and then consummated a merger that monopolized the integrated...
In the complaint dated March 30, 2001 the Commission alleged that Schering - Plough, the manufacturer of K-Dur 20 - a prescribed potassium chloride, used to treat patients with low blood potassium levels - entered into anticompetitive agreements with Upsher-Smith Laboratories and...
Under terms of a final consent order settling charges stemming from the merger of SmithKline and Glaxo Wellcome plc, the parties agreed to divest pharmaceutical products in six markets: antiemetics; the antibiotic, ceftazidime; oral and intravenous antiviral drugs for the treatment...

Pages